When people sleep with their heads elevated 20 degrees, their nocturnal IOP is lower than when they sleep with their heads flat, finds a newly published study.
When people sleep with their heads elevated 20 degrees, their nocturnal IOP is lower than when they sleep with their heads flat, finds a study newly published in the Journal of Glaucoma..
Thirty patients - 15 who said they had glaucoma and 15 who said they did not - participated in the prospective, non-randomized comparative case series. Each of them slept in a sleep laboratory on 2 different nights, 1 night lying in a supine position and the other lying on a wedge-shaped pillow at a 20-degree head-up position. The researchers measured baseline IOP at 10 pm while participants were awake and then measured IOP every 2 hours while participants slept, at midnight, 2 am, 4 am and 6 am.
Position did not significantly affect IOP as measured when participants were awake. When participants were sleeping, however, mean IOP was 1.51 mmHg higher when participants were in the supine position than when they were in the head-up position, with an average increase of 1.56 mmHg in those with glaucoma and 1.47 mmHg in those without the disease. In fact, 25 of the 30 patients had lower mean IOP when they were in the 20-degree head-up position than when lying flat. For 11 of them, mean IOP reduction was more than 10%.
To read an abstract of the study or download the full article, go to the journal's website.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.